News | Artificial Intelligence | November 18, 2019

The company will demonstrate the imaging platform in a new 3,200 sq. ft. booth in the North Hall, McCormick Place


November 18, 2019 — Visage Imaging, Inc. (Visage), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced Visage will be exhibiting under the theme of "Platform for the Future—Powered by Speed," highlighted by the demonstration of the Visage 7 Enterprise Imaging Platform, at the Radiological Society of North America (RSNA) 2019 annual meeting (Visage Booth 7524, McCormick Place-North Hall), Dec. 1-5, in Chicago, Ill.

Visage 7 has advanced Enterprise Imaging based on the proven ability to replace legacy PACS for imaging organizations of all sizes and local, regional or national scale. Five of the 2019-2020 top 20 ranked U.S. hospitals have chosen Visage 7, more than any other PACS.

One of the key drivers of this change has been the relentless growth of datasets produced by modern imaging modalities such as large cross-sectional (CT/MR) and digital breast tomosynthesis (DBT), and now high-resolution DBT ("High-res DBT"). These datasets, which are often combined with numerous prior imaging studies, are creating major bottlenecks for legacy 'compress and send' technology.

"The challenges of data explosion are placing significant stress on healthcare institutions, particularly when it comes to imaging," explained Malte Westerhoff, PhD, Visage Imaging Co-Founder and Chief Technology Officer. Westerhoff continued, "While we'll continue to successfully scale the underlying platform to cope with the exponentially growing compute and data handling requirements, that is only one part of the solution. Continuous innovation in how the system can aid and guide users in understanding data quickly, efficiently and reliably is also needed to allow users to benefit from the additional resolution and information contained in these growing datasets, instead of slowing them down. This involves user interface enhancements, AI-based data analysis and seamless information exchange with other IT systems in the modern enterprise."

At RSNA 2019, the following highlights will be demonstrated and discussed:

  • High-res DBT. Visage 7 supports the diagnostic interpretation of high-res DBT, delivered on-demand and in real-time, by ultrafast server-side processing.
  • Ophthalmology. With One Viewer, Visage 7 now supports even more clinical data, including PDF documents and ophthalmology images, enabling the elimination of legacy ophthalmology PACS.
  • Go-live flexibility. A Visage exclusive, Visage 7 enables customers to go-live enterprise-wide, assembling the imaging patient jacket on-the-fly with all priors, even if customer data migration is incomplete, from one or multiple PACS.
  • Breast MR multiparametric color maps. A preview of capabilities projected for Visage 7.1.15 will be demonstrated, including Breast MR multiparametric color maps for diffusion-weighted imaging as a works-in-progress (WIP). Visage 7 will be demonstrated with native, specialized toolsets for calculation and color mapped visualization of kinetic information in Breast MR images with elastic registration. 
  • Visage AI Accelerator. Visage will introduce the Visage AI Accelerator, an end-to-end AI solution that bridges both research and diagnostic imaging with the same, unified platform (WIP).
  • Visage 7 in the cloud. Highly optimized for cloud deployment, Visage 7 is the industry's first cloud-engineered server-side platform for complete PACS operations. Visage 7 in the cloud can offer the same ultrafast speed and functionality of on-premise implementations, but with the added security and scale of the cloud.
  • Visage 7 Workflow. Visage 7 now offers integrated, native workflow enabling customers to unify and manage reading worklists. Customers now have the choice of driving their reading workflow from independent workflow platforms, EHR-driven workflow, or natively with Visage 7.

Visage will be exhibiting in a new 3,200 sq. ft. booth in the North Hall, McCormick Place. To schedule a priority demonstration of Visage 7 or to meet with Visage at RSNA 2019, please visit this link for additional details.

For more information: www.visageimaging.com


Related Content

News | Radiology Imaging

Feb. 12, 2026 — Siemens Healthineers and Mayo Clinic are expanding their strategic collaboration to enhance patient care ...

Time February 13, 2026
arrow
News | Digital Pathology

Feb. 11, 2026 — Leica Biosystems has announced the global launch of the Leica CM1950 Cryostat with DualEcoTec Cooling ...

Time February 11, 2026
arrow
Feature | Cardiac Imaging | Kyle Hardner

Advances in coronary CT angiography (CCTA) have reached the point where image quality and AI capabilities are creating ...

Time February 06, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 5, 2026 — Eyas Medical Imaging, Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Time February 06, 2026
arrow
News | Ultrasound Women's Health

Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B ...

Time February 05, 2026
arrow
News | Lung Imaging

Feb. 3, 2026 — RevealDx, a leader in the characterization of lung nodules, recently announced FDA clearance of RevealAI ...

Time February 04, 2026
arrow
News | Radiation Therapy

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...

Time February 04, 2026
arrow
News | Radiology Imaging

Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's ...

Time February 04, 2026
arrow
News | FDA

Jan. 29, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MIM ...

Time February 03, 2026
arrow
News | FDA

Feb. 2, 2026 — Imagion Biosystems, Ltd. has submitted an Investigational New Drug (IND) application with the U.S. Food ...

Time February 02, 2026
arrow
Subscribe Now